
|Videos|August 11, 2021
Bausch + Lomb: clinical trial, pipeline updates for 2021
Author(s)Sheryl Stevenson, Alex Delaney-Gesing
Advertisement
Yolande Barnard, vice president and general manager of U.S. Pharmaceuticals at Bausch + Lomb, shares an update on the company's latest treatment for patients with DED associated with MGD as well as an investigational drug for the treatment of macular edema associated with uveitis.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
3
Neurotrophic keratitis outcomes improve with early, stage-based care
4
Alcon raises offer in amended deal to acquire STAAR Surgical
5













































.png)


